CN116867792A - 四环氧氮杂䓬化合物及其用途 - Google Patents

四环氧氮杂䓬化合物及其用途 Download PDF

Info

Publication number
CN116867792A
CN116867792A CN202280014071.XA CN202280014071A CN116867792A CN 116867792 A CN116867792 A CN 116867792A CN 202280014071 A CN202280014071 A CN 202280014071A CN 116867792 A CN116867792 A CN 116867792A
Authority
CN
China
Prior art keywords
unsubstituted
compound
substituted
pharmaceutically acceptable
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280014071.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·多
L·J·加扎德
S·A·格伦
M·L·兰德里
S·马尔霍特拉
M·休
程丽敏
Y-X·程
何明桃
信建峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN116867792A publication Critical patent/CN116867792A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280014071.XA 2021-02-09 2022-02-07 四环氧氮杂䓬化合物及其用途 Pending CN116867792A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021076369 2021-02-09
CNPCT/CN2021/076369 2021-02-09
CN2022074435 2022-01-27
CNPCT/CN2022/074435 2022-01-27
PCT/US2022/015407 WO2022173678A1 (en) 2021-02-09 2022-02-07 Tetracyclic oxazepine compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN116867792A true CN116867792A (zh) 2023-10-10

Family

ID=80445964

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280014071.XA Pending CN116867792A (zh) 2021-02-09 2022-02-07 四环氧氮杂䓬化合物及其用途

Country Status (11)

Country Link
US (2) US20220281893A1 (enExample)
EP (1) EP4291563A1 (enExample)
JP (1) JP7862413B2 (enExample)
KR (1) KR20230145078A (enExample)
CN (1) CN116867792A (enExample)
AU (1) AU2022218927A1 (enExample)
CA (1) CA3210167A1 (enExample)
IL (1) IL304700A (enExample)
MX (1) MX2023009135A (enExample)
TW (1) TWI824405B (enExample)
WO (1) WO2022173678A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430564A (zh) * 2023-10-18 2024-01-23 爱斯特（成都）生物制药股份有限公司 一种7-溴-2,6-二氯-5,8-二氟噻唑啉-4(3h)-酮的制备方法
CN119490512A (zh) * 2024-01-26 2025-02-21 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661556A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119684315A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
WO2025209456A1 (zh) * 2024-04-03 2025-10-09 北京泰德制药股份有限公司 血管紧张素ii 2型受体拮抗剂及其用于治疗癌性疼痛的用途
WO2025218798A1 (zh) * 2024-04-19 2025-10-23 领泰生物医药(绍兴)有限公司 Kras g12d降解剂及其制备方法和应用

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
MX2023015533A (es) * 2021-06-21 2024-01-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
CN115557974A (zh) * 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CN118019746A (zh) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
JP2025504041A (ja) * 2022-01-30 2025-02-06 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド キノリン系化合物及びその使用
EP4491673A4 (en) * 2022-03-08 2026-03-18 Shinetsu Chemical Co TWO-COMPONENT ADDITION-CURDED THERMOCONDUCTIVE SILICONE COMPOSITION, AND A HARDENED SILICONE OBJECT THEREIN
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN119365467A (zh) 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024008178A1 (zh) * 2022-07-08 2024-01-11 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN117430620A (zh) * 2022-07-22 2024-01-23 上海医药集团股份有限公司 嘧啶环类化合物、其中间体、其药物组合物及其应用
TW202409051A (zh) 2022-07-27 2024-03-01 大陸商江蘇恆瑞醫藥股份有限公司 稠環類化合物、其製備方法及其在醫藥上的應用
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
WO2024051721A1 (en) * 2022-09-07 2024-03-14 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024138486A1 (en) * 2022-12-29 2024-07-04 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
TW202426459A (zh) * 2022-09-23 2024-07-01 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
JP2025532125A (ja) * 2022-09-23 2025-09-29 アイディーエンス カンパニー リミテッド 新規なテトラヘテロサイクル化合物
TW202440594A (zh) * 2022-12-07 2024-10-16 大陸商北京加科思新藥研發有限公司 稠環化合物及其用途
JP2025541435A (ja) * 2022-12-23 2025-12-18 上海和誉生物医薬科技有限公司 Ｋｒａｓ ｇ１２ｄ阻害剤及びその応用
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
CN122187841A (zh) * 2023-01-18 2026-06-12 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
CN120548318A (zh) * 2023-01-18 2025-08-26 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
CN120500487A (zh) * 2023-01-18 2025-08-15 上海艾力斯医药科技股份有限公司 杂环类化合物、其药物组合物及其用途
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
WO2024178304A1 (en) * 2023-02-24 2024-08-29 Alterome Therapeutics, Inc. Kras modulators
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
EP4716531A2 (en) * 2023-05-22 2026-04-01 Board of Regents, The University of Texas System Heterocyclic compounds as nras inhibitors
CN121843945A (zh) * 2023-07-18 2026-04-10 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202540122A (zh) * 2023-11-22 2025-10-16 美商建南德克公司 Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025256655A1 (zh) * 2024-06-14 2025-12-18 上海翰森生物医药科技有限公司 一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026073024A1 (en) * 2024-09-30 2026-04-02 Gilead Sciences, Inc. Kras g12d inhibitors for the treatment of cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110603258A (zh) * 2017-05-11 2019-12-20 阿斯利康(瑞典)有限公司 抑制g12c突变型ras蛋白的杂芳基化合物
CN112074520A (zh) * 2018-05-08 2020-12-11 阿斯利康(瑞典)有限公司 四环杂芳基化合物
CN116113632A (zh) * 2021-03-30 2023-05-12 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
CN117083280A (zh) * 2021-03-07 2023-11-17 北京加科思新药研发有限公司 Kras g12d抑制剂的稠环衍生物
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN117242079A (zh) * 2021-07-23 2023-12-15 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
CN117255793A (zh) * 2021-06-21 2023-12-19 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
CN117916245A (zh) * 2021-08-31 2024-04-19 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2020097537A2 (en) * 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
WO2021215544A1 (en) * 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110603258A (zh) * 2017-05-11 2019-12-20 阿斯利康(瑞典)有限公司 抑制g12c突变型ras蛋白的杂芳基化合物
CN112074520A (zh) * 2018-05-08 2020-12-11 阿斯利康(瑞典)有限公司 四环杂芳基化合物
CN117083280A (zh) * 2021-03-07 2023-11-17 北京加科思新药研发有限公司 Kras g12d抑制剂的稠环衍生物
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN116113632A (zh) * 2021-03-30 2023-05-12 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
CN117255793A (zh) * 2021-06-21 2023-12-19 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
CN117242079A (zh) * 2021-07-23 2023-12-15 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
CN117916245A (zh) * 2021-08-31 2024-04-19 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430564A (zh) * 2023-10-18 2024-01-23 爱斯特（成都）生物制药股份有限公司 一种7-溴-2,6-二氯-5,8-二氟噻唑啉-4(3h)-酮的制备方法
CN119490512A (zh) * 2024-01-26 2025-02-21 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119613432A (zh) * 2024-01-26 2025-03-14 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661556A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119661555A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119684314A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119684315A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
CN119661555B (zh) * 2024-01-26 2026-04-14 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
WO2025209456A1 (zh) * 2024-04-03 2025-10-09 北京泰德制药股份有限公司 血管紧张素ii 2型受体拮抗剂及其用于治疗癌性疼痛的用途
WO2025218798A1 (zh) * 2024-04-19 2025-10-23 领泰生物医药(绍兴)有限公司 Kras g12d降解剂及其制备方法和应用

Also Published As

Publication number Publication date
AU2022218927A1 (en) 2023-08-03
US20250042919A1 (en) 2025-02-06
IL304700A (en) 2023-09-01
MX2023009135A (es) 2023-08-16
TW202241912A (zh) 2022-11-01
TWI824405B (zh) 2023-12-01
JP7862413B2 (ja) 2026-05-19
AU2022218927A9 (en) 2024-09-19
WO2022173678A1 (en) 2022-08-18
CA3210167A1 (en) 2022-08-18
US20220281893A1 (en) 2022-09-08
KR20230145078A (ko) 2023-10-17
JP2024506029A (ja) 2024-02-08
EP4291563A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
TWI824405B (zh) 四環氧氮呯化合物及其用途
TWI868441B (zh) 非環氧氮呯化合物及其用途
JP7735594B2 (ja) アザ四環式オキサゼピン化合物及びその使用
EP4605399A1 (en) Oxazepine compounds comprising a 6-aza moiety and uses thereof
CN118084868A (zh) 稠环化合物
CA3086867A1 (en) Fused ring compounds as ras protein inhibitors
WO2025194134A1 (en) Linearly substituted oxazepin-5-one kras-g12d inhibitors
HK40098150A (en) Tetracyclic oxazepine compounds and uses thereof
RU2783706C1 (ru) Соединения с конденсированными кольцами
HK40099028A (en) Oxazepine compounds and uses thereof in the treatment of cancer
HK40074677A (en) Bicyclic heteroaryl compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40098150

Country of ref document: HK